Zacks Investment Research upgraded shares of Cutera (NASDAQ:CUTR) from a sell rating to a hold rating in a report released on Tuesday.

According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “

A number of other brokerages also recently commented on CUTR. Roth Capital boosted their price objective on shares of Cutera from $41.00 to $47.00 and gave the company a buy rating in a research report on Tuesday, September 12th. Maxim Group downgraded shares of Cutera from a buy rating to a hold rating in a research report on Thursday, September 14th. Finally, BidaskClub raised shares of Cutera from a hold rating to a buy rating in a research report on Tuesday, December 12th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $37.33.

Shares of Cutera (NASDAQ CUTR) traded up $2.95 on Tuesday, reaching $49.35. 401,800 shares of the company were exchanged, compared to its average volume of 211,387. Cutera has a 52-week low of $18.00 and a 52-week high of $49.45. The stock has a market capitalization of $697.10, a P/E ratio of 65.80, a PEG ratio of 1.32 and a beta of 0.52.

Cutera (NASDAQ:CUTR) last announced its quarterly earnings data on Tuesday, November 7th. The medical device company reported $0.42 EPS for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.34. Cutera had a net margin of 7.99% and a return on equity of 18.73%. The firm had revenue of $38.17 million for the quarter, compared to the consensus estimate of $34.82 million. During the same period in the previous year, the firm posted $0.12 earnings per share. The firm’s revenue was up 26.1% on a year-over-year basis. equities research analysts forecast that Cutera will post 0.55 EPS for the current year.

In other Cutera news, EVP Larry Laber sold 5,843 shares of Cutera stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $45.35, for a total value of $264,980.05. Following the completion of the sale, the executive vice president now directly owns 79,463 shares in the company, valued at $3,603,647.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James A. Reinstein sold 7,175 shares of Cutera stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $45.35, for a total transaction of $325,386.25. Following the completion of the sale, the insider now owns 132,284 shares of the company’s stock, valued at $5,999,079.40. The disclosure for this sale can be found here. Insiders sold 37,968 shares of company stock valued at $1,676,086 over the last quarter. Corporate insiders own 3.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of CUTR. Bank of New York Mellon Corp lifted its stake in Cutera by 47.1% in the second quarter. Bank of New York Mellon Corp now owns 149,644 shares of the medical device company’s stock valued at $3,876,000 after acquiring an additional 47,926 shares during the last quarter. Federated Investors Inc. PA lifted its stake in shares of Cutera by 2.5% in the second quarter. Federated Investors Inc. PA now owns 58,415 shares of the medical device company’s stock worth $1,513,000 after buying an additional 1,427 shares during the last quarter. Wells Fargo & Company MN lifted its stake in shares of Cutera by 116.3% in the second quarter. Wells Fargo & Company MN now owns 42,960 shares of the medical device company’s stock worth $1,112,000 after buying an additional 23,097 shares during the last quarter. Alliancebernstein L.P. acquired a new stake in shares of Cutera in the second quarter worth $848,000. Finally, Martingale Asset Management L P lifted its stake in shares of Cutera by 9.0% in the second quarter. Martingale Asset Management L P now owns 55,905 shares of the medical device company’s stock worth $1,448,000 after buying an additional 4,600 shares during the last quarter. Hedge funds and other institutional investors own 87.64% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/01/12/cutera-cutr-upgraded-at-zacks-investment-research.html.

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Get a free copy of the Zacks research report on Cutera (CUTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related stocks with our FREE daily email newsletter.